logo-loader

Poolbeg Pharma announce two US patents

Published: 03:28 30 May 2022 EDT

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) (AIM:POLB, OTCQB:POLBF) has been granted US patents protecting two key assets – POLB 001, a potential flu treatment, and POLB 002, a nasal spray for virus infections.

Jeremy Skillington says the firm is working with its advisors to broaden and expand the patent families for both early-stage drug candidates.

He says the additional US patent protection of POLB 001 and POLB 002 is an important step in the commercialisation of these novel infectious disease products'.

Jeremy Skillington on Poolbeg's Rare Disease Strategy & New Developments

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce the company’s unaudited interim results for the first half of 2024, highlighting strong progress with its lead development candidate, POLB 001. As of 30 June 2024, the company reported a cash balance of £10.1...

on 09/18/2024
OSZAR »